Bausch Health Cos (BHC) Competitors

Bausch Health Cos (NYSE:BHC) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Which has higher earnings and valuation, BHC or BPMC?

Bausch Health Cos has higher revenue and earnings than Blueprint Medicines. Bausch Health Cos is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$9.73B	0.26	-$46M	-$0.11	-61.30
Blueprint Medicines	$508.82M	16.28	-$67.09M	-$2.47	-51.93

Is BHC or BPMC more profitable?

Bausch Health Cos has a net margin of -0.41% compared to Blueprint Medicines' net margin of -27.70%. Blueprint Medicines' return on equity of -64.60% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-0.41%	-540.45%	5.26%
Blueprint Medicines	-27.70%	-64.60%	-17.22%

Do institutionals & insiders believe in BHC or BPMC?

78.7% of Bausch Health Cos shares are held by institutional investors. 8.1% of Bausch Health Cos shares are held by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has more risk & volatility, BHC or BPMC?

Bausch Health Cos has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Does the media refer more to BHC or BPMC?

In the previous week, Bausch Health Cos and Bausch Health Cos both had 9 articles in the media. Blueprint Medicines' average media sentiment score of 1.23 beat Bausch Health Cos' score of 0.80 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Blueprint Medicines	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer BHC or BPMC?

Bausch Health Cos currently has a consensus price target of $7.42, indicating a potential upside of 9.99%. Blueprint Medicines has a consensus price target of $128.06, indicating a potential downside of 0.15%. Given Bausch Health Cos' higher possible upside, analysts clearly believe Bausch Health Cos is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86
Blueprint Medicines	0 Sell rating(s)	17 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.27

Summary

Bausch Health Cos and Blueprint Medicines tied by winning 8 of the 16 factors compared between the two stocks.